
CheckMate 7G8
NCT04149574
JCP074
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)
Status:
Recruiting

III
Phase

1st+
Line of Therapy

Relapsed / Recurrent / Refractory
Disease Stage

Biomarker(s)
PD-L1
Investigational
Product
Nivolumab
Treatment Arms
o Experimental: Arm A: nivolumab
o Placebo Comparator: Arm B: placebo +BCG